After 5-Year Winning Streak, Xarelto Makers Settle Personal Injury Suits

Bayer and Johnson & Johnson agree to resolve approximately 25,000 claims in federal and state courts for $775m, almost 13% of Xarelto's 2018 sales.

Johor,Malaysia-November 05,2017. Xarelto, medication to reduce stroke and blood clot by Bayer Healthcare. - Image

Despite winning the six Xarelto (rivaroxaban) product liability cases that went to trial, Bayer AG and Johnson & Johnson have decided to settle all ongoing litigation for $775m.

The co-marketers of Xarelto had been determined to avoid the path of Boehringer Ingelheim GmbH, which settled similar litigation...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet